Cardioprotective Angiotensin-(1-7) Peptide Acts as a Natural-Biased Ligand at the Angiotensin II Type 1 Receptor

Hypertension

Volumn 68, Issue 6, 2016, Pages 1365-1374

  Galandrin, Ségolène ^a   Denis, Colette ^a   Boularan, Cédric ^a   Marie, Jacky ^b   M'Kadmi, Céline ^b   Pilette, Claire ^c   Dubroca, Caroline ^c   Nicaise, Yvan ^d   Seguelas, Marie Hélène ^a   N'Guyen, Du ^a,d   Banères, Jean Louis ^b   Pathak, Atul ^a,d   Sénard, Jean Michel ^a,d   Galés, Céline ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c Cardiomedex SAS   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

angiotensin 1 7; angiotensin II type 1 receptor; biased agonism; G protein coupled receptor; renin angiotensin system; arrestin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN[1-7]; BETA ARRESTIN 2; GQ PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; PHENYLEPHRINE; UNCLASSIFIED DRUG; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN I (1-7); BETA ARRESTIN; CARDIOTONIC AGENT; PEPTIDE FRAGMENT;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HEART PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; CELL CULTURE; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM; MUSCLE; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; BETA-ARRESTINS; CARDIOTONIC AGENTS; CELLS, CULTURED; HEK293 CELLS; HUMANS; MUSCLES; PEPTIDE FRAGMENTS; PHENYLEPHRINE; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 84994881308     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.08118     Document Type: Article

References (51)

1. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev. 2008;13:367-375. doi: 10.1007/s10741-007-9060-z.
2. Robles NR, Cerezo I, Hernandez-Gallego R. Renin-angiotensin system blocking drugs. J Cardiovasc Pharmacol Ther. 2014;19:14-33. doi: 10.1177/1074248413501018.
3. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258-8263. doi: 10.1073/pnas.1432869100.
4. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol. 2008;585:303-312. doi: 10.1016/j.ejphar.2008.02.090.
5. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensinconverting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol. 2013;216:R1-R17. doi: 10.1530/JOE-12-0341.
6. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond). 2011;121:297-303. doi: 10.1042/CS20110036.
7. Daugherty A, Rateri DL, Howatt DA, Charnigo R, Cassis LA. PD123319 augments angiotensin II-induced abdominal aortic aneurysms through an AT2 receptor-independent mechanism. PLoS One. 2013;8:e61849. doi: 10.1371/journal.pone.0061849.
8. Lautner RQ, Villela DC, Fraga-Silva RA, et al. Discovery and characterization of alamandine: a novel component of the reninangiotensin system. Circ Res. 2013;112:1104-1111. doi: 10.1161/CIRCRESAHA.113.301077.
9. Tetzner A, Gebolys K, Meinert C, Klein S, Uhlich A, Trebicka J, Villacañas Ó, Walther T. G-protein-coupled receptor MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and phosphokinase A. Hypertension. 2016;68:185-194. doi: 10.1161/HYPERTENSIONAHA.116.07572.
10. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab. 2001;12:157-162.
11. Stragier B, De Bundel D, Sarre S, Smolders I, Vauquelin G, Dupont A, Michotte Y, Vanderheyden P. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail Rev. 2008;13:321-337. doi: 10.1007/s10741-007-9062-x.
12. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97. doi: 10.1152/ajpcell.00287.2006.
13. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953-970. doi: 10.1210/me.2004-0536.
14. Saulière A, Bellot M, Paris H, Denis C, Finana F, Hansen JT, Altié MF, Seguelas MH, Pathak A, Hansen JL, Sénard JM, Galés C. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol. 2012;8:622-630. doi: 10.1038/nchembio.961.
15. Patel PA, Tilley DG, Rockman HA. Physiologic and cardiac roles of beta-arrestins. J Mol Cell Cardiol. 2009;46:300-308. doi: 10.1016/j. yjmcc.2008.11.015.
16. Galandrin S, Oligny-Longpré G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci. 2007;28:423-430. doi: 10.1016/j.tips.2007.06.005.
17. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, Thomas WG. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol. 2002;61:768-777.
18. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A. 2003;100:10782-10787. doi: 10.1073/pnas.1834556100.
19. Strachan RT, Sun JP, Rominger DH, Violin JD, Ahn S, Rojas Bie Thomsen A, Zhu X, Kleist A, Costa T, Lefkowitz RJ. Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR). J Biol Chem. 2014;289:14211-14224. doi: 10.1074/jbc.M114.548131.
20. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, Coffman TM, Rockman HA, Lefkowitz RJ. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A. 2006;103:16284-16289. doi: 10.1073/pnas.0607583103.
21. Violin JD, Crombie AL, Soergel DG, Lark MW. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci. 2014;35:308-316. doi: 10.1016/j.tips.2014.04.007.
22. Felker GM, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Soergel DG, Teerlink JR, Violin JD, Voors AA, Pang PS. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail. 2015;3:193-201. doi: 10.1016/j.jchf.2014.09.008.
23. Bellot M, Galandrin S, Boularan C, et al. Dual agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-PKA signaling. Nat Chem Biol. 2015;11:271-279. doi: 10.1038/nchembio.1766.
24. Violin JD, Dewire SM, Barnes WG, Lefkowitz RJ. G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics. J Biol Chem. 2006;281:36411-36419. doi: 10.1074/jbc.M607956200.
25. Zhou Y, Dirksen WP, Babu GJ, Periasamy M. Differential vasoconstrictions induced by angiotensin II: role of AT1 and AT2 receptors in isolated C57BL/6J mouse blood vessels. Am J Physiol Heart Circ Physiol. 2003;285:H2797-H2803. doi: 10.1152/ajpheart.00466.2003.
26. Bae EH, Konvalinka A, Fang F, Zhou X, Williams V, Maksimowski N, Song X, Zhang SL, John R, Oudit GY, Pei Y, Scholey JW. Characterization of the intrarenal renin-angiotensin system in experimental alport syndrome. Am J Pathol. 2015;185:1423-1435. doi: 10.1016/j.ajpath.2015.01.021.
27. Zong WN, Yang XH, Chen XM, Huang HJ, Zheng HJ, Qin XY, Yong YH, Cao K, Huang J, Lu XZ. Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure. Acta Pharmacol Sin. 2011;32:1345-1350. doi: 10.1038/aps.2011.96.
28. Jalil JE, Palomera C, Ocaranza MP, Godoy I, Román M, Chiong M, Lavandero S. Levels of plasma angiotensin-(1-7) in patients with hypertension who have the angiotensin-I-converting enzyme deletion/deletion genotype. Am J Cardiol. 2003;92:749-751.
29. Nussberger J, Brunner DB, Nyfeler JA, Linder L, Brunner HR. Measurement of immunoreactive angiotensin-(1-7) heptapeptide in human blood. Clin Chem. 2001;47:726-729.
30. Velloso EP, Vieira R, Cabral AC, Kalapothakis E, Santos RA. Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I-converting enzyme deletion/deletion genotype. Braz J Med Biol Res. 2007;40:583-590.
31. Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin systems. Physiol Rev. 2006;86:747-803. doi: 10.1152/physrev.00036.2005.
32. van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser AH. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int. 2001;60:2311-2317. doi: 10.1046/j.1523-1755.2001.00049.x.
33. Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, Durand J, Hankes GH, Oparil S. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest. 1997;100:253-258. doi: 10.1172/JCI119529.
34. Silva SD Jr, Zampieri TT, Ruggeri A, Ceroni A, Aragão DS, Fernandes FB, Casarini DE, Michelini LC. Downregulation of the vascular reninangiotensin system by aerobic training-focus on the balance between vasoconstrictor and vasodilator axes. Circ J. 2015;79:1372-1380. doi: 10.1253/circj.CJ-14-1179.
35. Bertoncello N, Moreira RP, Arita DY, Aragão DS, Watanabe IK, Dantas PS, Santos R, Mattar-Rosa R, Yokota R, Cunha TS, Casarini DE. Diabetic Nephropathy Induced by Increased Ace Gene Dosage Is Associated with High Renal Levels of Angiotensin (1-7) and Bradykinin. J Diabetes Res. 2015;2015:674047. doi: 10.1155/2015/674047.
36. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007;73:463-469. doi: 10.1016/j.cardiores.2006.09.006.
37. Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep. 2008;10:410-414.
38. Koitka A, Cooper ME, Thomas MC, Tikellis C. Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol. 2008;35:420-425. doi: 10.1111/j.1440-1681.2008.04889.x.
39. Zimmerman B, Beautrait A, Aguila B, Charles R, Escher E, Claing A, Bouvier M, Laporte SA. Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal. 2012;5:ra33. doi: 10.1126/scisignal.2002522.
40. Gironacci MM, Coba MP, Peña C. Angiotensin-(1-7) binds at the type 1 angiotensin II receptors in rat renal cortex. Regul Pept. 1999;84:51-54.
41. Clark MA, Diz DI, Tallant EA. Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension. 2001;37:1141-1146.
42. Rowe BP, Saylor DL, Speth RC, Absher DR. Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. Regul Pept. 1995;56:139-146.
43. Clark MA, Tallant EA, Diz DI. Downregulation of the AT1A receptor by pharmacologic concentrations of Angiotensin-(1-7). J Cardiovasc Pharmacol. 2001;37:437-448.
44. Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K, Zhang C. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol. 2014;11:413-426. doi: 10.1038/nrcardio.2014.59.
45. Dupont AG, Yang R, Smolders I, Vanderheyden P. IRAP and AT(1) receptor mediated effects of angiotensin IV. J Intern Med. 2009;265:401-403; author reply 404. doi: 10.1111/j.1365-2796.2008.02027.x.
46. Zhuo JL, Li XC. New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides. 2011;32:1551-1565. doi: 10.1016/j.peptides.2011.05.012.
47. Feng YH, Noda K, Saad Y, Liu XP, Husain A, Karnik SS. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem. 1995;270:12846-12850.
48. Wright JW, Bechtholt AJ, Chambers SL, Harding JW. Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. Peptides. 1996;17:1365-1371.
49. Leduc M, Breton B, Galés C, Le Gouill C, Bouvier M, Chemtob S, Heveker N. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther. 2009;331:297-307. doi: 10.1124/jpet.109.156398.
50. Rajagopal S, Bassoni DL, Campbell JJ, Gerard NP, Gerard C, Wehrman TS. Biased agonism as a mechanism for differential signaling by chemokine receptors. J Biol Chem. 2013;288:35039-35048. doi: 10.1074/jbc.M113.479113.
51. Thompson GL, Lane JR, Coudrat T, Sexton PM, Christopoulos A, Canals M. Biased agonism of endogenous opioid peptides at the μ-opioid receptor. Mol Pharmacol. 2015;88:335-346. doi: 10.1124/mol.115.098848.